American College of Medical Genetics and Genomics (ACMG)

acmg.net

The American College of Medical Genetics and Genomics (ACMG) provides education, resources and a voice for the medical genetics and genomics profession. To make genetic services available to and improve the health of the public, the ACMG promotes the development and implementation of methods to diagnose, treat and prevent genetic diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

news image

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More

ILLUMINA INTRODUCES NEW PAN-CANCER COMPANION DIAGNOSTIC TO MATCH PATIENTS WITH RARE GENETIC MUTATIONS TO TARGETED THERAPY

Illumina | May 27, 2022

news image

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patien...

Read More

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

news image

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

news image

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More
news image

Industrial Impact

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More
news image

ILLUMINA INTRODUCES NEW PAN-CANCER COMPANION DIAGNOSTIC TO MATCH PATIENTS WITH RARE GENETIC MUTATIONS TO TARGETED THERAPY

Illumina | May 27, 2022

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patien...

Read More
news image

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More
news image

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us